Patents by Inventor Tai-gyu Kim

Tai-gyu Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12215136
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Grant
    Filed: April 4, 2023
    Date of Patent: February 4, 2025
    Assignee: The Catholic University of Korea Industry—Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
  • Patent number: 12077779
    Abstract: The present invention relates to a novel feeder cell and a method for growing gamma delta T cells using the same. More specifically, a large amount of gamma delta T cells may be grown in vitro with high purity and without simulation of a T cell receptor by using a feeder cell into which costimulatory molecules are introduced and a low concentration of IL-2, differentiation into central memory cells may be possible when stimulated, activity by the feeder cell, and cytolytic against tumour cells is provided.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: September 3, 2024
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Hyun Woo Cho, Su Yeon Kim
  • Publication number: 20240277775
    Abstract: The present invention relates to the pharmaceutical use of a cord blood immunosuppressive cell and, more specifically, the present invention provides the use of a human-derived cord blood immunosuppressive cell, which is selected in accordance with analysis of function and phenotype and a classification standard, as a new cell therapy product for anti-inflammation, anti-fibrosis, and prevention or treatment of myocardial infarction.
    Type: Application
    Filed: June 14, 2021
    Publication date: August 22, 2024
    Inventors: Hyun Jung SOHN, Tai Gyu KIM, Su Eon KIM, Soo Hyun JUNG, Hyun ll CHO, Bang Geul LIM, Eun Ah KIM
  • Patent number: 12054752
    Abstract: The present invention relates to a HLA-A2 subtype-specific PLK1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein. More specifically, a HLA-A2 subtype-specific PLK-1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein according to the present invention can provide a CD8+ T cell immune response specific for tumor cells.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: August 6, 2024
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tai Gyu Kim, Hyun Il Cho, Un Hee Kim
  • Patent number: 11859207
    Abstract: The present invention relates to an artificial antigen-presenting cell prepared from an HLA-null cell line by using a multiplex CRISPR-Cas9 system and the use thereof and, more particularly, to a novel artificial antigen-presenting cell which includes the ability to present antigens of HLA class I and a co-stimulatory molecule group transferred from an HLA-A, -B, -C null cell line generated using a multiplex CRISPR-Cas9 system and to stimulate T cells, an immunotherapeutic agent using the same, and the use thereof for treating tumors, pathogenic infections, and autoimmune diseases.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 2, 2024
    Assignee: The Catholic Uiversity of Korea Industry-Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Cheol Hwa Hong
  • Publication number: 20230287347
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Application
    Filed: April 4, 2023
    Publication date: September 14, 2023
    Inventors: Tai Gyu KIM, Hyun Jung SOHN, Su Eon KIM
  • Publication number: 20230218678
    Abstract: The present invention relates to a cord blood plasma-derived exosome or a mimetic thereof and a pharmaceutical use thereof. More particularly, the present invention provides the use of a human cord blood plasma-derived exosome or an exosome mimetic that mimics the proteomic profile of the cord blood plasma-derived exosome for the improvement, prevention or treatment of various autoimmune diseases or wound healing.
    Type: Application
    Filed: March 18, 2021
    Publication date: July 13, 2023
    Inventors: Tai Gyu KIM, Su Eon KIM
  • Patent number: 11649436
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 16, 2023
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
  • Publication number: 20200115684
    Abstract: The present invention relates to a HLA-A2 subtype-specific PLK1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein. More specifically, a HLA-A2 subtype-specific PLK-1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein according to the present invention can provide a CD8+ T cell immune response specific for tumor cells.
    Type: Application
    Filed: June 12, 2018
    Publication date: April 16, 2020
    Inventors: Tai Gyu KIM, Hyun Il CHO, Un Hee KIM
  • Publication number: 20200071668
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 5, 2020
    Inventors: Tai Gyu KIM, Hyun Jung SOHN, Su Eon KIM
  • Publication number: 20190309260
    Abstract: The present invention relates to an artificial antigen-presenting cell prepared from an HLA-null cell line by using a multiplex CRISPR-Cas9 system and the use thereof and, more particularly, to a novel artificial antigen-presenting cell which includes the ability to present antigens of HLA class I and a co-stimulatory molecule group transferred from an HLA-A, -B, -C null cell line generated using a multiplex CRISPR-Cas9 system and to stimulate T cells, an immunotherapeutic agent using the same, and the use thereof for treating tumors, pathogenic infections, and autoimmune diseases.
    Type: Application
    Filed: December 1, 2017
    Publication date: October 10, 2019
    Inventors: Tai Gyu KIM, Hyun Jung SOHN, Cheol Hwa HONG
  • Publication number: 20190284532
    Abstract: The present invention relates to a novel feeder cell and a method for growing gamma delta T cells using the same. More specifically, a large amount of gamma delta T cells may be grown in vitro with high purity and without simulation of a T cell receptor by using a feeder cell into which costimulatory molecules are introduced and a low concentration of IL-2, differentiation into central memory cells may be possible when stimulated, activity by the feeder cell, and cytolytic against tumour cells is provided.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 19, 2019
    Inventors: Tai Gyu KIM, Hyun Jung SOHN, Hyun Woo CHO, Su Yeon KIM
  • Patent number: 10251936
    Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: April 9, 2019
    Assignee: The Catholic Unviersity of Korea Industry-Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Il Cho
  • Publication number: 20180326003
    Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 15, 2018
    Inventors: Tai Gyu KIM, Hyun Il CHO
  • Publication number: 20180216065
    Abstract: The present invention relates to a method for inducing differentiation myeloid-derived suppressor cells from cord blood CD34 positive cells and proliferating the same, and a use of the myeloid-derived suppressor cells. More specifically, myeloid-derived suppressor cells are induced to differentiate and proliferated by culturing cord blood CD34 positive cells in the presence of a cytokine cocktail of GM-CSF and SCF, such that myeloid-derived suppressor cells can be mass-produced in vitro, and the myeloid-derived suppressor cells can be used in preventing or treating immunorejection-related diseases such as graft-versus-host disease.
    Type: Application
    Filed: July 20, 2016
    Publication date: August 2, 2018
    Applicant: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventors: Tai Gyu KIM, Mi Young PARK
  • Patent number: 9993526
    Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: June 12, 2018
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Tai Gyu Kim, Hyun Il Cho
  • Patent number: 9821044
    Abstract: The present invention relates to a CD4 T cell vaccine and a use thereof, and provides a CD4 T cell vaccine which can increase intracellular viability and effectively induce an antigen-specific cytotoxic T lymphocyte (CTL) response.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 21, 2017
    Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventors: Tai Gyu Kim, Hyun Il Cho, Hye Mi Park
  • Publication number: 20170056473
    Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
    Type: Application
    Filed: October 30, 2015
    Publication date: March 2, 2017
    Inventors: Tai Gyu KIM, Hyun Il CHO
  • Publication number: 20160136251
    Abstract: The present invention relates to a CD4 T cell vaccine and a use thereof, and provides a CD4 T cell vaccine which can increase intracellular viability and effectively induce an antigen-specific cytotoxic T lymphocyte (CTL) response.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 19, 2016
    Inventors: Tai Gyu Kim, Hyun Il Cho, Hye Mi Park
  • Patent number: 9072690
    Abstract: The present invention relates to tumor antigen proteins or genes derived from polo-like kinase 1. As a result of the formation of a complex by binding polo-like kinase 1-derived proteins or variants having characteristics functionally identical to the proteins with MHC class I antigens or II antigens, the complex can be recognized by cytotoxic T lymphocytes. Therefore, the polo-like kinase 1-derived proteins or variants are identified as a tumor antigen which can be generally used in tumor immunotherapy.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: July 7, 2015
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Tai Gyu Kim